KEITH LASHINSKI: Open Payments
NPI 1952736472 · SCRANTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$556 in 31 payments from 10 companies in 2025. Trend: 2023 $411 · 2024 $596 · 2025 $556
Food & beverage: $556
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $99 |
| Novartis Pharmaceuticals Corporation | 5 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $74 |
| SCPHARMACEUTICALS INC. | 3 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $64 |
| Novo Nordisk Inc | 4 | $62 |
| BridgeBio Pharma, Inc. | 2 | $34 |
| ABIOMED | 1 | $34 |
| Edwards Lifesciences Corporation | 1 | $32 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: CAMZYOS, LEQVIO, JARDIANCE, FUROSCIX, Kerendia, Wegovy, Attruby, ELIQUIS.
Industry payments across PA — which companies pay providers there.
